Overview

PLM60 for Peripheral T Cell Lymphoma (PTCL)

Status:
Withdrawn

Trial end date:
2025-01-01

Target enrollment:

Participant gender:

Summary

This is a Phase 1-2, randomized, multicenter, open label study of PLM60 administered via intravenous (IV) infusion in 28 day treatment cycles to adult participants with relapsed or refractory Peripheral T Cell Lymphoma (PTCL).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Conjupro Biotherapeutics
Conjupro Biotherapeutics, Inc.

Collaborator:

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.